| *Sponsored
(Nasdaq: SHPH) Jumps Post-Bell On Breaking News (Green Surge Follows Patent Announcement)
April 10th Greetings, Friend!
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) made some serious moves after Thursday's closing bell.
Why? Part of it could be due to SHPH dropping breaking news. Take a look:
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic program
Dr. Alan Kozikowski, internationally acclaimed pioneer in the discovery of a critical PSMA targeting ligand for clinical applications is co-inventor
Theranostic molecule designed to preferentially target prostate cancer cells to the effects of radiation and chemotherapeutic agents
GAITHERSBURG, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), ..., today announced the filing of a key provisional patent application with the United States Patent and Trademark Office (USPTO) entitled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.”
The filing is yet another critical advancement within the Company’s Diagnostic subsidiary which aims to develop highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and for targeted therapy delivery using radio labelled PSMA ligands.
...
“I believe a significant opp. exists for PSMA ligands for prostate cancer diagnosis and treatment,” commented Anatoly Dritschilo, MD, Shuttle Pharma’s Chairman and Chief Scientific Officer. “The Shuttle Pharma scientists have collaborated with Dr. Kozikowski on discovery projects for radiation sensitizing drugs and have recently focused on discovery of novel PSMA ligands with the intent of targeting prostate cancer cells preferentially to the effects of radiation and chemotherapeutic agents. We look forward to the continued advancement of our Shuttle Diagnostics’ subsidiary and the opp. to develop a theranostic that has the potential to play a significant role in the future diagnosis and treatment of prostate cancer.”
...
Read the full article here.
Don't forget. This is a low float profile with fewer than 4Mn shares in its float which means volatility potential could be heightened (especially after positive news like we just saw above).
Consider (Nasdaq: SHPH) for your radar Friday and read my initial report below right now. -----
With the markets experiencing heightened instability, many are looking for ways to adapt.
One area worth watching is low float profiles—these often exhibit volatile movements, especially during turbulent periods.
Why now? When uncertainty rises, liquidity dynamics shift, and low float profiles can react sharply to catalysts or sentiment changes.
This creates potential for swift chart movements, though it’s essential to keep a close watch on these types of profiles.
The key is staying informed.
And right now, I've got a new Nasdaq breakout idea coming your way.
Best part? It has a low float of fewer than 4Mn shares which means volatility potential will need to be watched for closely.
Not only that, it has significant news throughout the beginning of 2025.
The only thing missing? Wall Street's complete attention.
But before that can happen, this company is topping my watchlist right now:
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)
Founded in 2012 by Georgetown University Medical Center faculty, Shuttle Pharmaceuticals is a discovery and developmental stage specialty pharmaceutical company focused on improving outcomes for cancer patients undergoing radiation therapy (RT).
The company develops innovative therapies to enhance RT efficacy, target cancer cells, protect healthy tissue, and harness the immune response, aiming to increase cure rates, prolong survival, and improve quality of life.
Shuttle's Key Areas of Focus
Radiation Sensitizers: Shuttle Pharmaceuticals’ lead candidate, Ropidoxuridine (IPdR), is an oral halogenated pyrimidine designed to sensitize cancer cells to radiation. It incorporates into the DNA of rapidly growing cancer cells, increasing their vulnerability to radiation-induced damage. Currently in Phase II trials for glioblastoma, Ropidoxuridine has FDA Orphan Drug Designation.
HDAC Inhibitors: Using proprietary technology, Shuttle has developed selective histone deacetylase (HDAC) inhibitors that regulate gene expression by modifying chromatin structure. These inhibitors aim to restore tumor suppressor gene function and enhance RT efficacy. Three lead candidates are in preclinical development targeting solid tumors.
Prostate Cancer Diagnostics: Shuttle is advancing a predictive biomarker strategy to develop diagnostic tests for prostate cancer patients undergoing RT. These tests aim to assess treatment success risk and guide therapeutic decisions.
Grab Key Source Details Here: SHPH Website. SHPH Presentation. -----
Consider These 5 Potential Catalysts For (Nasdaq: SHPH) Right Now
Low Float Volatility Potential: With approximately 3.62Mn shares in its float, SHPH may experience the potential for heightened volatility in a flash.
Phase II Trial Progress: Achieving 25% enrollment in its Phase II trial for glioblastoma highlights progress toward identifying optimal dosing and demonstrating survival benefits compared to historical controls.
PSMA Development Agreement: Collaboration with UCSF aims to advance a boron-containing PSMA ligand for prostate cancer diagnosis and therapy, leveraging theranostic approaches for imaging and treatment.
Leadership Expansion: Appointment of Christopher Cooper as Co-CEO enhances business operations while allowing scientific leadership to focus on clinical advancements.
Debt Elimination: Paying off its Senior Secured Convertible Note provides financial flexibility to advance the ongoing Phase II trial and other key initiatives. -----
Shuttle Pharmaceuticals continues to drive innovation in precision oncology through its dual-functional molecules, diagnostic technologies, and strategic partnerships. Its mission remains focused on improving outcomes for cancer patients worldwide.
Coverage is officially initiated on Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH). I'll be in touch with more info soon!
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/10/2025 and ending on 04/11/2025 to publicly disseminate information about (SHPH:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (SHPH:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/shph/#details | 
0 Response to "(Nasdaq: SHPH) Jumps Post-Bell On Breaking News (Green Surge Follows Patent Announcement)"
Post a Comment